JP2022550037A - 局所進行性扁平上皮癌を有する患者の治療のための投与レジメン - Google Patents
局所進行性扁平上皮癌を有する患者の治療のための投与レジメン Download PDFInfo
- Publication number
- JP2022550037A JP2022550037A JP2022518772A JP2022518772A JP2022550037A JP 2022550037 A JP2022550037 A JP 2022550037A JP 2022518772 A JP2022518772 A JP 2022518772A JP 2022518772 A JP2022518772 A JP 2022518772A JP 2022550037 A JP2022550037 A JP 2022550037A
- Authority
- JP
- Japan
- Prior art keywords
- administered
- compound
- pharmaceutically acceptable
- acceptable salt
- human patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962905703P | 2019-09-25 | 2019-09-25 | |
| US62/905,703 | 2019-09-25 | ||
| US202063016762P | 2020-04-28 | 2020-04-28 | |
| US63/016,762 | 2020-04-28 | ||
| EP20184601 | 2020-07-07 | ||
| EP20184601.1 | 2020-07-07 | ||
| PCT/EP2020/076994 WO2021058794A1 (en) | 2019-09-25 | 2020-09-25 | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022550037A true JP2022550037A (ja) | 2022-11-30 |
| JP2022550037A5 JP2022550037A5 (cg-RX-API-DMAC7.html) | 2023-10-02 |
Family
ID=72644266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022518772A Pending JP2022550037A (ja) | 2019-09-25 | 2020-09-25 | 局所進行性扁平上皮癌を有する患者の治療のための投与レジメン |
Country Status (13)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024022275A1 (zh) * | 2022-07-29 | 2024-02-01 | 苏州科睿思制药有限公司 | Xevinapant的晶型及其制备方法和用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019122941A1 (en) * | 2017-12-21 | 2019-06-27 | Debiopharm International Sa | Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2525585T3 (es) | 2006-05-05 | 2014-12-26 | The Regents Of The University Of Michigan | Intermedios para la preparación de miméticos de SMAC bivalentes |
| BRPI0711591A2 (pt) | 2006-05-16 | 2011-11-16 | Aegera Therapeutics, Inc. | composto de ligação de domìnio bir da iap |
| WO2008014229A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| WO2008014240A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| PE20110217A1 (es) | 2006-08-02 | 2011-04-01 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| WO2008128171A2 (en) * | 2007-04-13 | 2008-10-23 | The Regents Of The University Of Michigan | Diazo bicyclic smac mimetics and the uses thereof |
| EP2296650B1 (en) | 2008-05-16 | 2020-05-06 | Novartis AG | Immunomodulation by iap inhibitors |
| US20100317593A1 (en) | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
| ES2643233T3 (es) | 2009-10-23 | 2017-11-21 | The Regents Of The University Of Michigan | Miméticos de SMAC bicíclicos diazo bivalentes y los usos de los mismos |
| EP2493879B1 (en) | 2009-10-28 | 2014-05-14 | Joyant Pharmaceuticals, Inc. | Dimeric smac mimetics |
| CA2780130A1 (en) | 2009-11-05 | 2011-05-12 | The Uab Research Foundation | Treating basal-like genotype cancers |
| JP2014528409A (ja) | 2011-09-30 | 2014-10-27 | テトラロジック ファーマシューティカルズ コーポレーション | 増殖性疾患(がん)の治療において使用するためのSMAC模倣体(ビリナパント(birinapant)) |
| US8859541B2 (en) | 2012-02-27 | 2014-10-14 | Boehringer Ingelheim International Gmbh | 6-alkynylpyridines |
| AU2013306087B2 (en) | 2012-08-23 | 2017-08-10 | The Regents Of The University Of Michigan | Bivalent inhibitors of IAP proteins and therapeutic methods using the same |
| CA2896577C (en) | 2012-11-30 | 2024-01-23 | Sanford-Burnham Medical Research Institute | Inhibitor of apoptosis protein (iap) antagonists |
| WO2014121178A1 (en) | 2013-02-04 | 2014-08-07 | Tetralogic Pharmaceuticals Corp. | Smac mimetic method of treatment |
| US9278978B2 (en) | 2013-08-23 | 2016-03-08 | Boehringer Ingelheim International Gmbh | 6-Alkynyl Pyridine |
| US9249151B2 (en) | 2013-08-23 | 2016-02-02 | Boehringer Ingelheim International Gmbh | Bis-amido pyridines |
| CN115368356B (zh) | 2013-12-20 | 2025-05-09 | 阿斯特克斯治疗有限公司 | 双环杂环化合物及其治疗用途 |
| AR101479A1 (es) | 2014-08-11 | 2016-12-21 | Boehringer Ingelheim Int | Derivados de 6-alquinil-piridina |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| AU2015360095B2 (en) * | 2014-12-09 | 2020-02-27 | Advenchen Laboratories Nanjing Ltd | Quinoline derivative against non-small cell lung cancer |
| CA2916970A1 (en) | 2016-01-08 | 2017-07-08 | Pharmascience Inc. | A smac mimetic compound for use in the treatment of proliferative diseases |
| EP3419643A4 (en) | 2016-02-24 | 2020-04-01 | Children's Hospital of Eastern Ontario Research Institute Inc. | SMC COMBINATION THERAPY FOR TREATING CANCER |
| CN110475567A (zh) | 2017-03-31 | 2019-11-19 | 勃林格殷格翰国际有限公司 | 抗癌组合疗法 |
-
2020
- 2020-09-25 AU AU2020356356A patent/AU2020356356A1/en not_active Abandoned
- 2020-09-25 CA CA3151770A patent/CA3151770A1/en active Pending
- 2020-09-25 CN CN202080079488.5A patent/CN114727984A/zh active Pending
- 2020-09-25 WO PCT/EP2020/076994 patent/WO2021058794A1/en not_active Ceased
- 2020-09-25 MX MX2022003628A patent/MX2022003628A/es unknown
- 2020-09-25 EP EP20780195.2A patent/EP4034102A1/en not_active Withdrawn
- 2020-09-25 US US17/761,503 patent/US20250268863A1/en not_active Abandoned
- 2020-09-25 BR BR112022005624A patent/BR112022005624A2/pt not_active IP Right Cessation
- 2020-09-25 PH PH1/2022/550721A patent/PH12022550721A1/en unknown
- 2020-09-25 JP JP2022518772A patent/JP2022550037A/ja active Pending
- 2020-09-25 KR KR1020227013744A patent/KR20220088700A/ko not_active Ceased
-
2022
- 2022-03-24 IL IL291682A patent/IL291682A/en unknown
- 2022-04-20 CO CONC2022/0004947A patent/CO2022004947A2/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019122941A1 (en) * | 2017-12-21 | 2019-06-27 | Debiopharm International Sa | Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule |
Non-Patent Citations (2)
| Title |
|---|
| CHRISTOPHE LE TOURNEAU, ET AL.: "A phase I/II randomized study of Debio1143 combined with concurrent chemoradiation therapy (CCRT) in", MEETING ABSTRACT, 2014 ASCO ANNUAL MEETING, JOURNAL OF CLINICAL ONCOLOGY, vol. Vol.32, No.15_suppl, JPN6024034251, 20 May 2014 (2014-05-20), ISSN: 0005536693 * |
| RADIOTHERAPY AND ONCOLOGY, vol. 119, no. 1, JPN6024034252, 2016, pages 245 - 246, ISSN: 0005536694 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20250268863A1 (en) | 2025-08-28 |
| PH12022550721A1 (en) | 2024-05-13 |
| AU2020356356A1 (en) | 2022-05-12 |
| IL291682A (en) | 2022-05-01 |
| MX2022003628A (es) | 2022-07-21 |
| CA3151770A1 (en) | 2021-04-01 |
| CO2022004947A2 (es) | 2022-08-30 |
| EP4034102A1 (en) | 2022-08-03 |
| CN114727984A (zh) | 2022-07-08 |
| KR20220088700A (ko) | 2022-06-28 |
| WO2021058794A1 (en) | 2021-04-01 |
| BR112022005624A2 (pt) | 2022-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP7579465B2 (ja) | 頭頸部癌の治療のためのegfr阻害剤 | |
| CN103533961B (zh) | 以表皮生长因子受体为靶向的治疗癌症的组合方法 | |
| JP7332293B2 (ja) | バルリチニブおよび抗癌剤を含んでなる併用療法 | |
| Cho et al. | Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer | |
| JP2019530752A (ja) | がんを治療するための薬物の調製における、抗pd‐1抗体とvegfr阻害剤とを組み合わせた使用 | |
| JP2016523858A (ja) | がんを治療するためのbtk阻害剤とフルオロウラシルとの併用 | |
| JP2021054832A (ja) | 薬学的組み合わせ | |
| KR20200096788A (ko) | 화학치료법-내성 난소암 또는 유방암 치료에서 parp 억제제의 용도 | |
| US20250127759A1 (en) | Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer | |
| CN103533940A (zh) | 治疗晚期实体瘤的方法 | |
| WO2015185011A1 (zh) | 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物 | |
| CN115803629A (zh) | 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法 | |
| TW202535477A (zh) | 抗b7h3抗體—藥物偶聯物治療癌症的方法 | |
| CN101687104A (zh) | 包括长春氟宁和曲妥单抗的癌症治疗联合疗法 | |
| US12611403B2 (en) | Combined pharmaceutical composition of c-Met kinase inhibitor and anti-PD-L1 antibody | |
| CN113194941A (zh) | 使用包括akt抑制剂、紫杉烷和pd-l1抑制剂的组合疗法治疗乳腺癌 | |
| JP2025509278A (ja) | 小細胞肺癌を治療する方法 | |
| US20250268863A1 (en) | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma | |
| US20190276439A1 (en) | Method of treating solid tumors | |
| WO2023281413A1 (en) | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer | |
| CN113573707A (zh) | 用于治疗癌症的组合产品 | |
| CN114667159B (zh) | 喹啉衍生物与pd-1单抗的药物组合 | |
| HK40122430A (en) | Method for treating cancer with anti-b7h3 antibody-drug conjugate | |
| WO2024231875A1 (en) | Hpk1 inhibitor for use in the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230922 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230922 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240828 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250226 |